Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
April 21 2020 - 02:36PM
- Former senior executive at AstraZeneca and
pharmaceutical industry expert to join as Independent
Director
- The Company is developing Vicromax(tm) – a
broad-spectrum orally administered anti-viral candidate for
COVID-19
- Upon receipt of FDA approval, Phase II
clinical trial is planned to be conducted at Mayo
Clinic
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) today appointed Mr. Anthony (‘Tony’) Zook to the Board
of Directors of its majority-owned subsidiary ViralClear
Pharmaceuticals, Inc.
Mr. Zook brings to ViralClear a wealth of commercialization
experience in the pharmaceutical industry gained primarily through
his career at AstraZeneca Plc [LON:AZN]. Mr. Zook held several
executive positions at AstraZeneca, including Executive Vice
President of Global Commercial Operations from 2010 to 2013,
President and Chief Executive Officer of the North American
division from 2007 to 2010 and President of Medimmune, the wholly
owned biologics division of AstraZeneca, from 2008 to 2010. Under
Mr. Zook’s leadership, AstraZeneca commercialized ten blockbuster
brands, each in excess of $1 billion in sales. Along with the
CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio
Investment Board (PIB), which set and approved the overall strategy
for Research and Development and allocated resources by therapeutic
area. Mr. Zook served or continues to serve on several boards
including the boards of AltheRx, Inhibikase, Rib-X Pharmaceuticals,
the National Pharmaceutical Council, PhRMA, the Pennsylvania
Division of the American Cancer Society and his alma mater,
Frostburg State University. Mr. Zook earned a B.S. degree from
Frostburg State University and an A.A. degree in chemical
engineering from Pennsylvania State University.“I have been very
impressed with what the ViralClear team achieved in just one month.
The strong fundamentals of its product candidate, the safety it
demonstrated in the previous trials and the recently secured
clinical support of Mayo Clinic are very important elements needed
to help take the product into FDA-approved clinical trials and
then, hopefully, upon FDA approval, to the commercial market. I
look forward to lending my expertise and see this company advance
in the coming months,” commented Mr. Zook.
The Company recently announced that Mayo Clinic is set to
become a study site for a planned Vicromax(tm) Phase II clinical
trial for the treatment of COVID-19, once approved by the FDA. The
study will be a randomized, placebo-controlled trial. Data from the
Phase II trial is expected within three months from its
commencement.“Tony’s many commercial accomplishments in the
pharmaceutical industry and his executive experience in leading
both large and small companies adds a definite advantage to
ViralClear. We look forward to Tony’s contributions as we continue
to execute on our goals of bringing Vicromax(tm) to patients,”
stated Kenneth L. Londoner, Chairman and CEO of BioSig
Technologies, Inc.
About Vicromax(tm) (merimepodib)Anti-viral
candidate Vicromax (tm) (merimepodib orMMPD) targets RNA-dependant
polymerases. The molecule has shown activity against a broad
spectrum of RNA viruses and has demonstrated satisfactory safety
data from over 300 patients treated for hepatitis C. Recently, the
Company published first pre-clinical data generated under contract
with Galveston National Laboratory at The University of Texas
Medical Branch. A manuscript titled “The IMPDH inhibitor
merimepodib suppresses SARS-COV-2 replications” was authored by
Natalya Bukreyeva, Emily K. Mantlo, Rachel A. Sattler, Cheng Huang,
Slobodan Paessler, DVM, Ph.D of the UTMB Galveston National
Laboratory and Jerome Zeldis, M.D., Ph.D of ViralClear. In-vitro
studies referenced in the manuscript demonstrated that merimepodib
decreased viral production by over 98%. About BioSig
Technologies BioSig Technologies is a medical technology
company commercializing a proprietary biomedical signal processing
platform designed to improve signal fidelity and uncover the full
range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About ViralClearBioSig’s subsidiary ViralClear
Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical
to treat COVID-19. Vicromax(tm) is intended to be an orally
administered, broad-spectrum anti-viral agent that has demonstrated
strong activity against COVID-19 in cell cultures in laboratory
testing. The product candidate has completed Phase I and three
Phase II trials in other indications.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2023 to Mar 2024